Article information
Full text is only aviable in PDF
References
[1.]
K.A. Papp, S. Tyring, M. Lahfa, J. Prinz, C.E.M. Griffiths, A.M. Nakanishi, et al.
A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction.
Br J Dermatol, 152 (2005), pp. 1304-1312
[2.]
S. Tyring, K.B. Gordon, Y. Poulin, R.G. Langley, A.B. Gottlieb, M. Dunn, et al.
Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.
Arch Dermatol, 143 (2007), pp. 719-726
[3.]
V. García-Patos Briones.
Seguridad de etanercept.
Actas Dermosifiliogr, 96 (2005), pp. 25-32
[4.]
J.L. Sánchez-Carazo, L.M. Santos, V.O. Martínez.
Safety of etanercept in psoriasis: a critical review.
Drug Saf, 29 (2006), pp. 675-685
[5.]
A. Romero-Maté, C. García-Donoso, S. Córdoba-Guijarro.
Efficacy and safety of Etanercept in psoriasis/psoriatic arthritis.
Am J Clin Dermatol, 8 (2007), pp. 143-155
[6.]
S. Domm, J. Cinatl, U. Mrowietz.
The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature.
Br J Dermatol, 159 (2008), pp. 1217-1228
[7.]
L. Leal, M. Ribera, E. Daudén.
Psoriasis e infección por el virus de la inmunodeficiencia humana.
Actas Dermosifiliogr, 99 (2008), pp. 753-763
[8.]
W.-H. Boehncke, R.A. Brasie, J. Barker, S. Chimenti, E. Daudén, M. de Rie, et al.
Recommendations for use of etanercept in psoriasis: a European dermatology expert group consensus.
J Eur Acad Dermatol Venereol, 20 (2006), pp. 988-998
[9.]
M. Filippova, H. Song, J.L. Connolly, T.S. Dermody, P.J. Duerksen-Hughes.
The human papillomavirus 16 E6 protein binds to tumor necrosis factor (TNF) R1 and protects cells from TNFinduced apoptosis.
J Biol Chem, 277 (2002), pp. 21730-21739
[10.]
J.M. Routes, K. Morris, M.C. Ellison, S. Ryan.
Macrophages kill human papillomavirus type 16 E6-expressing tumor cells by tumor necrosis factor alpha- and nitric oxide-dependent mechanisms.
J Virol, 79 (2005), pp. 116-123
[11.]
D.R. Adams, A.L. Zaenglein, M.S. Hershey.
Etanercept and warts.
J Drugs Dermatol, 3 (2004), pp. 601
[12.]
C. Antoniou, M.G. Kosmadaki, A.J. Stratigos, A.D. Katsambas.
Genital HPV lesions and molluscum contagiosum occurring in patients receiving anti-TNF-alpha therapy.
Dermatology, 216 (2008), pp. 364-365
[13.]
Registro Español de Acontecimientos Adversos de Terapias Biológicas en Enfermedades Reumáticas (Biobadaser). [accessed October, 2008]. Available from: http://biobadaser.ser.es/
Copyright © 2010. Academia Española de Dermatología y Venereología and Elsevier España, S.L.
